Cleveland BioLabs Inc. [NASDAQ: CBLI] closed the trading session at $2.33 on 09/11/20. The day’s price range saw the stock hit a low of $1.88, while the highest price level was $2.38. The company report on June 3, 2020 that Cleveland BioLabs Closes $3.175 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules.
BUFFALO, NY / ACCESSWIRE / June 3, 2020 / Cleveland BioLabs, Inc. (CBLI), today announced the closing of its previously announced registered direct offering to several institutional and accredited investors of an aggregate of 1,515,878 shares of its common stock, at a purchase price of $2.0945 per share. The offering was priced at-the-market under Nasdaq rules. Cleveland BioLabs also issued to the investors unregistered warrants to purchase up to an aggregate of 757,939 shares of common stock. The warrants have an exercise price equal to $2.033 per share, are exercisable immediately upon issuance and will expire five years from the issuance date.
The gross proceeds from the offering were approximately $3.175 million. The Company currently intends to use the net proceeds from the offering for general corporate purposes.
The stocks have a year to date performance of 287.04 percent and weekly performance of 41.21 percent. The stock has been moved at 0.00 percent over the last six months. The stock has performed -11.07 percent around the most recent 30 days and changed 49.20 percent over the most recent 3-months.
If compared to the average trading volume of 1.45M shares, CBLI reached to a volume of 1203004 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cleveland BioLabs Inc. [CBLI]:
Oppenheimer have made an estimate for Cleveland BioLabs Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on January 24, 2014. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Buy. The new note on the price target was released on March 21, 2013, representing the official price target for Cleveland BioLabs Inc. stock. Previously, the target price had yet another raise to $3, while Oppenheimer analysts kept a Outperform rating on CBLI stock.
The Average True Range (ATR) for Cleveland BioLabs Inc. is set at 0.20, with the Price to Sales ratio for CBLI stock in the period of the last 12 months amounting to 27.44.
CBLI stock trade performance evaluation
Cleveland BioLabs Inc. [CBLI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 41.21. With this latest performance, CBLI shares dropped by -11.07% in over the last four-week period, additionally sinking by 0.00% over the last 6 months – not to mention a rise of 128.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CBLI stock in for the last two-week period is set at 55.08, with the RSI for the last a single of trading hit 64.21, and the three-weeks RSI is set at 53.06 for Cleveland BioLabs Inc. [CBLI]. The present Moving Average for the last 50 days of trading for this stock 2.36, while it was recorded at 1.99 for the last single week of trading, and 1.89 for the last 200 days.
Cleveland BioLabs Inc. [CBLI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cleveland BioLabs Inc. [CBLI] shares currently have an operating margin of -212.03. Cleveland BioLabs Inc.’s Net Margin is presently recorded at -237.73.
Reflecting on the efficiency of the workforce at the company, Cleveland BioLabs Inc. [CBLI] managed to generate an average of -$220,582 per employee. Receivables Turnover for the company is 3.53 with a Total Asset Turnover recorded at a value of 0.34.Cleveland BioLabs Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
Cleveland BioLabs Inc. [CBLI]: Insider Ownership positions
There are presently around $1 million, or 7.20% of CBLI stock, in the hands of institutional investors. The top three institutional holders of CBLI stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 273,251, which is approximately -5.564% of the company’s market cap and around 64.39% of the total institutional ownership; VANGUARD GROUP INC, holding 52,592 shares of the stock with an approximate value of $0.12 million in CBLI stocks shares; and BARCLAYS PLC, currently with $0.1 million in CBLI stock with ownership of nearly New of the company’s market capitalization.
Positions in Cleveland BioLabs Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 6 institutional holders increased their position in Cleveland BioLabs Inc. [NASDAQ:CBLI] by around 50,328 shares. Additionally, 4 investors decreased positions by around 42,135 shares, while 9 investors held positions by with 323,648 shares. The mentioned changes placed institutional holdings at 416,111 shares, according to the latest SEC report filing. CBLI stock had 3 new institutional investments in for a total of 44,892 shares, while 3 institutional investors sold positions of 26,035 shares during the same period.